Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

Goldstein "Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial" J Natl Cancer Inst (2015) 10.1093/jnci/dju413

[4]

Rowinsky "Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting" J Clin Oncol (1993) 10.1200/jco.1993.11.10.2010

[5]

Hausheer "Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy" Semin Oncol (2006) 10.1053/j.seminoncol.2005.12.010

[6]

Park "Chemotherapy-induced peripheral neurotoxicity: a critical analysis" CA Cancer J Clin (2013) 10.3322/caac.21204

[7]

Desai "Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel" Clin Cancer Res (2006) 10.1158/1078-0432.ccr-05-1634

[8]

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

William J. Gradishar, Sergei Tjulandin, Neville Davidson et al.

Journal of Clinical Oncology 2005 10.1200/jco.2005.04.937

[9]

Gradishar "Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer" J Clin Oncol (2009) 10.1200/jco.2008.18.5397

[10]

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

Mark A. Socinski, Igor Bondarenko, Nina A. Karaseva et al.

Journal of Clinical Oncology 2012 10.1200/jco.2011.39.5848

[11]

National Cancer Institute (2006)

[12]

Tabernero "Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer" Oncologist (2015) 10.1634/theoncologist.2014-0394

[13]

Sakai "Nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC): analysis of peripheral neuropathy" (2013)

[14]

Von Hoff "Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial" J Clin Oncol (2011) 10.1200/jco.2011.36.5742

[15]

Goldstein "Evaluation of peripheral neuropathy in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) vs gem alone for patients with metastatic adenocarcinoma of the pancreas" (2013)

[16]

Park "Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes" BMC Cancer (2014) 10.1186/1471-2407-14-993

[17]

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al.

New England Journal of Medicine 2011 10.1056/nejmoa1011923

[18]

Gresham "Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis" BMC Cancer (2014) 10.1186/1471-2407-14-471

[19]

Sprowl "Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2" Proc Natl Acad Sci U S A (2013) 10.1073/pnas.1305321110

[20]

(2014)

[21]

de Gramont "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer" J Clin Oncol (2000) 10.1200/jco.2000.18.16.2938

[22]

Park "Long-term neuropathy after oxaliplatin treatment: challenging the dictum of reversibility" Oncologist (2011) 10.1634/theoncologist.2010-0248

[23]

Bennett "Impact of oxaliplatin-induced neuropathy: a patient perspective" Support Care Cancer (2012) 10.1007/s00520-012-1428-5

Metrics

41

Citations

23

References

Details

Published: Jan 01, 2016
Vol/Issue: 52
Pages: 85-91
License: View

Authors

D

David Goldstein

Prince of Wales Hospital, University of New South Wales, Cancer Survivors Centre, Sydney, Australia

Vall d'Hebron University Hospital and Institute of Oncology, Barcelona, Spain

H

Helen Liu

Simon Fraser University Burnaby Canada

Cite This Article

David Goldstein, Daniel D. Von Hoff, Malcolm Moore, et al. (2016). Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT). European Journal of Cancer, 52, 85-91. https://doi.org/10.1016/j.ejca.2015.10.017

Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT)

You May Also Like